Members only Markets Featured Bitcoin ETFs Just Erased a Year of Inflows. Who's Left to Buy? US spot bitcoin ETFs just flipped to net outflows for 2026 after a $1.28 billion exit week. Every leg of this cycle was carried by a different buyer — and the flow data now shows who's left.
Paid-members only Markets Featured $FLY Hit an All-Time Low 24 Hours Before Landing a $1.3 Billion Engine Deal: What the Headline Number Is Really Made Of, the Burn Clock It Resets, and the Zones From $14.44 to $26.86 Into Tuesday's Earnings Firefly Aerospace fell to $14.44 Wednesday, then jumped 36.8% Friday on a $1.3B AST SpaceMobile engine deal and a NASA CLPS 2 seat, with Q3 earnings due Tuesday after the close. The $400M cash vs locked-stock split, the $106M quarterly burn it lands on, and scenario zones from $14.44 to $26.86.
Members only Space Economy Featured The ISS Comes Down in 2030. The Race to Replace It Just Got a Deadline. NASA's final solicitation for commercial space stations is out and bids are due December 8. Four companies are in, the crew-transport math is unsolved, and only one public stock carries direct exposure to the April award.
Paid-members only Markets Featured Top 10 Stocks We're Watching This Week — Inflation Week Edition Tuesday's CPI arrives with no annual rate, CoreWeave prints Tuesday night, Take-Two reports ten days before GTA VI ships, and Cisco and Applied Materials close the week Thursday. Brent just crashed from $117 to $98. Nine of ten report earnings; the tenth is the policy trade the midterms created.
Paid-members only Investing Featured The First Drug That Might Slow Huntington's Finally Has an FDA Date. The Market Sold the News. uniQure's one-time gene therapy just got priority review and a May 1, 2027 decision date — the first in Huntington's history. The stock fell anyway. At $750 million of enterprise value net of cash, the gap between milestone and market is the trade.
Members only Macro Featured The Last Major Central Bank Just Joined the War Economy The Bank of England raised rates for the first time since 2023 — 8 to 1, with the dissent wanting double. Gilts above 5%, a 25% energy-cap jump landing in January, and a December meeting that is suddenly live.
Macro Featured America Is Hiring Again. The Unemployed Can't Tell. October's 165,000-job blowout hid the longest average job search since 2016. The labor market has split in two — and the low jobless-claims data is part of the illusion.
Members only Markets Featured Every Central Bank Is Hiking. Mexico Just Cut. The same day the Bank of England joined the global hiking cycle, Banxico defied every forecast with a 3–2 cut to 6.25%. The peso fell, stocks rallied, and the carry cushion over the Fed is down to 225 basis points. Here's what the divergence is pricing.
Members only Geopolitics Featured The 1.5°C Era Is Over. The Fight Over Who Pays for What Comes Next Starts Monday. COP31 opens Monday in Antalya as the first climate summit of the overshoot era: the 1.5°C target is gone, the U.S. is out of Paris, and a $7.5 trillion finance gap is the only agenda item that matters for markets.
Members only Macro Featured 76 Million Americans Just Got a Raise. The Fund That Pays It Has Six Years Left. Social Security's 3.6% COLA is the largest since 2023 — and a live readout of reaccelerating inflation. The fund paying it burned $200 billion last year, and the official clock now stops in 2032.
Markets Featured Nobody Voted to End the AI Trade. Wall Street Sold It Anyway. A $2.9 trillion single-session wipeout, the Nasdaq in correction, and semiconductors' worst day since 2020. Inside the three forces that broke the AI trade on Thursday — and what today's jobs report means for the bounce.
Paid-members only Markets Featured $IONQ Printed a $564 Million Profit at a 52-Week Low While Losing $433 Million From Operations: The Warrant Math, the Real Growth Rate, and the Wall at $69.46 IonQ beat on revenue, raised 2026 guidance to $515M, and reported its first GAAP profit, a day after hitting a 52-week low. The $896M warrant gain that created the profit, the acquired half of the 336% growth, the $3.7B war chest, and scenario zones from $24.92 to $69.46.
Paid-members only Investing Featured On Black Friday, the FDA Rules on a Disease That Has Never Had a Drug BridgeBio lost 72% in a day in 2021. Five years later it runs a $1 billion-rate heart drug and faces three FDA decisions in seven months — starting November 27, with the first potential approval for any form of limb-girdle muscular dystrophy.
Paid-members only Markets Featured $SEZL Raised Guidance a Fourth Time With 23% of the Float Short: The 955,000 Subscribers, the 2.7% Loss Line, and What 19 Times Next Year Is Pricing Sezzle beat on revenue and earnings, raised 2026 guidance a fourth time, and guided 2027 above consensus, with 23% of the float still short. The take-rate machine, the credit-loss math, the falling share count, and scenario zones from $136.69.
Markets Featured The First Thanksgiving Without Spirit Airlines Will Be the Most Expensive in a Decade Thanksgiving airfare is at a decade high and bookings are falling. Crude just crashed 15% on peace talks - and airlines say your ticket won't follow it down. What Spirit's collapse in May really took out of the market.
Members only Markets Featured Turkey's Stock Market Lost $128 Billion. The Man Who Ran It Is in Jail. A $19 billion fund freeze, 455,758 trapped investors, the Borsa Istanbul chief jailed for bribery, and MSCI weighing demotion: inside the scandal stress-testing Turkey's entire capital market.
Members only Markets Featured Disney's New CEO Wants 20% Back. Thousands of Jobs Are the Down Payment. Seven months into Josh D'Amaro's tenure, Disney is preparing thousands of layoffs and asking managers for 20% cost cuts — while the stock sits near a 52-week high and a double-digit EPS promise comes due November 17.
Paid-members only Markets Featured $SMCI Just Printed a $19.9 Billion Quarter and the Market Shrugged: The 44% Customer, the 12% Margin, and What Six Times Earnings Is Pricing Supermicro grew revenue 298% and raised its full-year guide, yet trades at six times forward earnings. One customer was 44% of the quarter, gross margin fell to 12.7%, and operations burned cash. The concentration math, the balance sheet, and scenario zones from $31.
Markets Featured Seven Flips and a Veto Pen: What the Midterm Wipeout Means for Markets Democrats flipped seven Senate seats and took the House. Markets sold the shock overnight, then bought the gridlock. What actually changes for policy and positioning — and what doesn't.
Members only Space Economy Featured Amazon's Space Internet Is Ready. The Rockets Aren't. On November 13, ULA's grounded Vulcan rocket flies again — carrying 40 satellites for Amazon's answer to Starlink. What the launch means for AMZN, BA, LMT, and NOC.
Members only Energy Featured Why Data Centers Are Buying Old Jet Engines Gas turbines are sold out to 2032 and prices are up 50% in a year — so data centers are bolting retired jet engines to concrete. Inside the first quarter where the scarcity trade blinked.
Paid-members only Markets Featured $INO: A 268% Pop, a Going-Concern Warning, and 91 Million Warrants Nobody Counted The FDA approved Inovio's VOCERYQ and the stock nearly quadrupled overnight. The approval is real. So are the going-concern warning and 91 million warrants struck between $1.10 and $3.76. The dilution math, the November 4 Precigen read-through, and scenario zones for the week.
Finance Featured The Biggest Heist in History Took 20 Minutes North Korea drained $6.3 billion from Binance across ten blockchains — most of it in about 20 minutes. How the attack worked, why the stablecoin freeze race clawed back $2.7 billion, and what the record heist reveals about where power actually sits in crypto.
Healthcare Featured Washington Started Paying for Weight-Loss Drugs. Your Boss Started Canceling the Coverage. On July 1, Medicare began covering Wegovy and Zepbound for a $50 copay. The same autumn, large employers cut GLP-1 coverage for the first time in three years. The same drug now costs $50 or $300 depending on which card you carry.
Paid-members only Defence Featured America Can't Forge Its Own Artillery Shells A $469 million plant was supposed to deliver two-thirds of US 155mm shell capacity. As of March, it has produced zero compliant rounds. The Pentagon's own watchdog explains why — and which defense primes carry the risk.